碘-123标记血管内皮生长因子在胶质瘤中的预后价值
该研究纳入23例经组织病理学证实的原发性脑肿瘤患者,行[123I]-VEGF SPECT显像(注射后30分钟和18小时),其中8例加做[11C]-MET PET,评估T/N比值与总生存的关系。结果显示WHO IV级胶质瘤在注射后18小时可见[123I]-VEGF摄取,而II/III级为阴性;[123I]-VEGF T/N比值阈值<1.32者生存显著长于≥1.32者(2680天 vs 295天,P<0.05)。作者认为[123I]-VEGF显像可能有助于肿瘤血管生成的显示,并可能提供胶质瘤患者的预后信息。
要点
- WHO IV级胶质瘤在注射后18小时显示[123I]-VEGF摄取,II/III级为阴性。
- [123I]-VEGF T/N比值<1.32者生存2680天,显著长于≥1.32者的295天(P<0.05)。
- 16例IV级胶质瘤中,T/N比值<1.75者生存720天,显著长于≥1.75者的183天(P<0.05)。
核心结论
- 作者认为[123I]-VEGF显像可能有助于肿瘤血管生成的显示,并可能为胶质瘤患者提供相关预后信息。
研究设计与样本
- 纳入23例经组织病理学证实的原发性脑肿瘤连续患者(9例女性、14例男性,年龄30-83岁,平均年龄56.6±14.4岁),均行[123I]-VEGF SPECT脑显像(注射后30分钟和18小时),其中8例加做[11C]-MET PET,采用T/N比值进行视觉和半定量评估,通过ROC分析确定T/N比值阈值,采用Kaplan-Meier法估计总生存。
主要发现
- WHO IV级胶质瘤病灶在注射后18小时显示[123I]-VEGF摄取,而II级或III级其他脑肿瘤显示阴性结果。
- [123I]-VEGF阳性和阴性肿瘤之间肿瘤大小无显著差异。
- [123I]-VEGF T/N比值阈值<1.32的患者生存显著长于T/N比值≥1.32的患者(2680天 vs 295天;P<0.05)。
- 在16例IV级胶质瘤亚组中,以T/N比值1.75为阈值发现总生存显著差异(T/N比值<1.75:720天;T/N比值≥1.75:183天;P<0.05)。
- [11C]-MET PET T/N比值在IV级胶质瘤(平均T/N比值3.71)与II级或III级胶质瘤(平均T/N比值1.74)之间差异显著(P<0.05)。
关键数值与推荐
- [123I]-VEGF T/N比值预后阈值经ROC分析确定:全组为1.32,16例IV级胶质瘤亚组为1.75。
- [11C]-MET PET T/N比值:IV级胶质瘤平均3.71,II级或III级胶质瘤平均1.74(P<0.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Recent studies have shown that tumor vascular endothelial cells and various tumor cells overexpress receptors for vascular endothelial growth factor (VEGF). The aim of this study was to investigate the prognostic value of [123I]-VEGF scintigraphy in patients with histologically verified brain tumors. METHODS: 23 consecutive patients (9 women and 14 men aged 30-83 years, mean age 56.6 ± 14.4 years) with histopathologically-verified primary brain tumors were included in the study. All patients had undergone [123I]-VEGF scintigraphy. SPECT examinations of brain were performed 30 min and 18 h after injection. Additional [11C]-methionine PET ([11C]-MET PET) was performed in eight of the 23 patients. Both [123I]-VEGF and [11C]-MET PET were evaluated visually and semiquantitatively by tumor-to-normal brain uptake ratio (T/N ratio). Thresholds of the T/N ratio were evaluated by analysis of receiver operating characteristics (ROC). Overall survival (OS) was estimated using the Kaplan-Meier method. RESULTS: World Health Organization (WHO) grade IV glioma lesions showed [123I]-VEGF uptake 18 h after the injection, whereas other brain tumors of grade II or III showed negative results. There was no significant difference in the tumor size between VEGF positive and VEGF negative tumors. Patients with [123I]-VEGF T/N ratio threshold <1.32 showed significantly longer survival than patients with T/N ratio ≥ 1.32 (2680 days vs 295 days; P < 0.05). In the subgroup of 16 grade IV glioma patients, significant OS differences were found using a T/N ratio of 1.75 as threshold (T/N ratio < 1.75: 720 days; T/N ≥ 1.75: 183 days; P < 0.05). Significant difference (P < 0.05) was also found in [11C]-MET PET T/N ratios between the grade IV glioma (mean T/N ratio: 3.71) and the grade II or III glioma (mean T/N ratio: 1.74). CONCLUSION: Our results suggest that [123I]-VEGF scintigraphy may be useful for visualization of tumor angiogenesis. In addition, [123I]-VEGF may provide relevant prognostic information in patients with glioma.
引用
- Rainer E, Wang H, Traub-Weidinger T, et al. The prognostic value of [123I]-vascular endothelial growth factor ([123I]-VEGF) in glioma. Eur J Nucl Med Mol Imaging. 2018. PMID: 30062604. doi:10.1007/s00259-018-4088-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。